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Abstract 
Background: Comorbidity in people with asthma can significantly increase asthma morbidity and 
lower adherence to asthma guidelines.  
Objective: The objective of this study was to comprehensively measure the prevalence of physical 
and mental health comorbidities in adults with asthma using a large nationally representative 
population. 
Methods: Cross-sectional analysis of routine primary care electronic medical records for 1,424,378 
adults in the UK, examining the prevalence of 39 comorbidities in people with and without asthma, 
before and after adjustment for age, sex, social deprivation and smoking status using logistic 
regression. 
Results: Of 39 comorbidities measured, 36 (92%) were significantly more common in adults with 
asthma. 62.6% of adults with asthma had ≥1 comorbidity vs. 46.2% of those without, and 16.3% had 
≥4 comorbidities vs. 8.7% of those without.  Comorbidities with the largest absolute increase in 
prevalence in adults with asthma were: COPD (13.4% vs 3.1%), depression (17.3% vs 9.1%), painful 
conditions (15.4% vs 8.4%), and dyspepsia (10.9% vs 5.2%). Comorbidities with the largest relative 
difference in adults with asthma compared to without were: COPD (adjusted odds ratio [aOR] 5.65, 
95%CI 5.52-5.79), bronchiectasis (aOR 4.65, 95%CI 4.26-5.08), eczema/psoriasis (aOR 3.30, 95%CI 
3.14-3.48), dyspepsia (aOR 2.20, 95%CI 2.15-2.25) and chronic sinusitis (aOR 2.12, 95%CI 1.99-2.26). 
Depression and anxiety were more common in adults with asthma (aOR 1.60, 95%CI 1.57-1.63, and 
aOR 1.53, 95%CI 1.48-1.57 respectively). 
Conclusions and Clinical Relevance: Physical and mental health comorbidity is the norm in adults 
with asthma. Appropriate recognition and management should form part of routine asthma care. 
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Introduction 
Asthma is a worldwide public health problem associated with a high economic cost and is the second 
most common chronic illness in primary care with 6.0% of the UK population being actively 
treated.[1][2] Comorbidities are important to recognise in people with asthma because they can 
complicate the clinical care of patients with asthma in a variety of ways.[3][4] First comorbidities 
may present with similar symptoms as those associated with poor asthma control. This could lead to 
under or overtreatment of asthma through misdiagnosis, increasing treatment burden and 
unnecessary cost.[5] Second, potentially beneficial effects of treatment for some comorbidities may 
be withheld in people with asthma due to safety concerns, such as beta-blockers for the 
management of cardiovascular disease or anxiety.[6][7] Third, people living with asthma may be at 
increased risk of developing other conditions, which may lower adherence to asthma therapy and 
increase asthma morbidity. For example, comorbid depression or anxiety may lead to poorer asthma 
outcomes and is associated with increasing asthma severity.[8][9] In many instances, the importance 
of these problems in absolute terms is directly related to the prevalence of the comorbidity of 
interest in people with asthma.  
 
Existing studies investigating the prevalence of comorbidity in people with asthma have typically 
measured a limited number of comorbidities, used small population samples, or have not always 
adjusted for important confounders, such as smoking and social deprivation, which are strongly 
associated with the number of physical and mental health comorbidities.[10] Understanding 
patterns of comorbidity in adults with asthma is therefore important to help health care 
professionals contextualise asthma care, not least because recommended treatments based on 
evidence from clinical trials typically include selected populations whose narrow age and eligibility 
criteria mean that many people with comorbidity may be excluded. For example Travers et al found 
that 64-100% (median 96%) of people with spirometry or peak flow variability defined asthma 
identified from a population survey would have been excluded from 17 key asthma trials 
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underpinning the Global Initiative for Asthma (GINA) guidelines.[11] This is important because a 
medicines benefit risk balance may be less favourable in people with certain comorbidities such as 
the cardiovascular risk from beta2-agonists.[12] The aim of this study was therefore to measure the 
prevalence of comorbid physical and mental health conditions in people with asthma and to 
compare this with a general population of adults without asthma, adjusting for confounders 
including age, gender, smoking and social deprivation. 
 
Methods 
Data source 
The design was a cross-sectional analysis of an established database containing electronic medical 
records for 1,424,378 adults aged 18 and over from 314 primary care practices in Scotland, UK on 
31st March 2007. The UK National Health Service (NHS) requires registration with a single primary 
care practice, and 98% of people in Scotland are registered with a general practice. The data covers 
approximately one third of the Scottish population, and is nationally representative in terms of age, 
sex and socioeconomic deprivation.[13]  
 
Asthma definition 
People with active asthma aged 18 and over were identified by them having a Read Code for asthma 
ever recorded ever, no recent Read Code for asthma resolved, and having been prescribed one or 
more asthma medications in the 12 months prior to data extraction. This definition matches that 
used in the UK Quality and Outcomes Framework, a national programme which incentivises 
practices to maintain disease registers for selected conditions including asthma, used to define 
asthma are shown in the online supporting information appendix 1.  
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Other morbidities 
Data on 39 common and important comorbidities were extracted as described previously (please 
refer to appendix table for details of selection process).[14] Data were extracted on age, sex, 
smoking status and socioeconomic deprivation measured using the Carstairs deprivation score. The 
Carstairs score is a measure of neighbourhood socioeconomic deprivation assigned to individuals 
based on their postcode of residence, and has been widely used in healthcare research.[15][16]  
 
Statistical analysis 
The prevalence of each of the 39 different comorbidities was measured in people with and without 
asthma. Univariate and multivariate logistic regression was used to estimate odds ratios with 95% 
confidence intervals (95%CI) for the prevalence of each of 31 physical conditions in adults with 
asthma compared to the general adult population, adjusted for age, sex, smoking status and 
socioeconomic deprivation measured by quintiles (equal fifths of the Scottish population) of the 
Carstairs score. This analysis was repeated for eight mental health conditions, with a further 
adjustment for the total number of physical conditions since physical disease burden is known to be 
strongly associated with the presence of depression.[14] All general practices contributing data gave 
explicit permission to use the anonymised data for research and the NHS Grampian Research Ethics 
Committee had agreed that individual studies did not require ethical approval. Data were analysed 
using IBM SPSS v22.  
 
Results   
Of 1,424,378 adults in the dataset, 84,505 had active asthma (prevalence = 5.9%, 95% CI 5.89 to 
5.97). The characteristics of adults with and without asthma are shown in table 1. A larger 
proportion of adults with asthma were women (58.7% vs 50.4% without), were non-smokers and 
were living in more deprived areas.  
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Comorbidities in adults with asthma 
The crude prevalence of comorbidity was significantly greater in people with asthma compared to 
the general population.  The crude prevalence of people with one or more health condition was 
62.6% in adults with asthma compared to only 46.2% in those without asthma (table 1). The crude 
prevalence of people with ≥4 health conditions was 16.3% in people with asthma compared to 8.7% 
in those without. In unadjusted analysis, adults with asthma had on average 1.6 more comorbid 
health conditions (95% CI 1.59 to 1.62, p<0.0001) compared to adults without asthma.  
The crude prevalence of physical and mental health conditions in adults with and without asthma 
are shown in tables 2 and 3. The crude prevalence of the most frequently recorded comorbidities in 
adults with asthma in order of frequency were: hypertension (20.1%), depression (17.3%), pain 
(15.9%), COPD (13.4%) and dyspepsia (10.9%). Comorbidities with the greatest absolute percentage 
difference in prevalence in people with asthma compared to adults without, in order of frequency 
were: COPD (absolute percentage difference [APD] 10.3%, 95%CI 19.1 to 10.5), depression (APD 
8.2%, 95%CI 7.4 to 7.9), painful conditions (APD 7.5%, 95%CI 7.2 to 7.7), dyspepsia (APD 5.7%, 95%CI 
5.5 to 5.9) and hypertension (APD 3.9%, 95%CI 3.6 to 4.2). 
 
Following adjustment for age, sex, deprivation and smoking status, 29 (94%) of the 31 physical 
comorbidities and 7 (88%) of the 8 mental health comorbidities were significantly more common in 
adults with asthma compared to those without (table 2 and 3 respectively). In relative terms, the 
comorbidities most likely to be present in adults with asthma compared to adults in the general 
population following multivariate adjustment were: COPD (adjusted OR [aOR] 5.65, 95%CI 5.52 to 
5.79), bronchiectasis (aOR 4.65, 95%CI 4.26 to 5.08), eczema/psoriasis (aOR 3.30, 95%CI 3.14 to 
3.48), dyspepsia (aOR 2.20, 95%CI 2.15 to 2.25) and chronic sinusitis (aOR 2.12 95%CI 1.99 to 2.26). 
Additionally, adults with asthma were also more likely to have other important physical 
comorbidities not classically associated with asthma including pain (aOR 2.04, 95%CI 1.99 to 2.08), 
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migraine (aOR 1.97, 95%CI 1.85 to 2.10), heart failure (aOR 1.47, 95%CI 1.39 to 1.55), coronary heart 
disease (aOR 1.39, 95%CI 1.35 to 1.43) and epilepsy (aOR 1.29, 95%CI 1.21 to 1.38).  
 
Of the mental health conditions examined, people with asthma were significantly more likely to have 
depression (aOR 1.60, 95%CI 1.57 to 1.63) and anxiety (aOR 1.53, 95%CI 1.48 to 1.57). Associations 
with other mental health conditions were weaker, and only dementia had a significantly lower 
likelihood of being recorded in adults with asthma than those without (aOR 0.60, 95%CI 0.55 to 
0.66).  
 
Discussion 
This study investigating the prevalence of comorbidity in adults with asthma using a large nationally 
representative population showed that comorbidity is the norm in adults with asthma, with 62.6% of 
people having one or more comorbidity. Of the 39 comorbidities evaluated, 36 (92.3%) occurred 
more often in people with asthma, including depression, anxiety, coronary heart disease, epilepsy, 
migraine and pain. Hypertension was the most prevalent physical condition identified in both 
groups, but still had one of the largest absolute percentage differences in prevalence in adults with 
asthma, with the others being COPD, depression, pain and dyspepsia. In relative terms however, the 
comorbidities most likely to be present in people with asthma compared to the general population 
were COPD, bronchiectasis, eczema, dyspepsia and chronic sinusitis.  
 
Several studies have previously measured the prevalence of comorbidity in people with asthma. A 
Canadian claims-based study examined differences in comorbidity according to 14 disease categories 
reporting a 50% greater relative risk of comorbidity among those with asthma compared to those 
without.[17] A study from the United States found that 26% of people with asthma had one or more 
comorbidities whilst 10% had three or more, however this study only measured 5 comorbid 
conditions.[18] Similar findings were observed in a study from Germany examining only 8 
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comorbidities, which reported that 26% of people with asthma had at least one comorbidity and 
17% had two or more conditions.[19] A greater proportion of patients in our study had at least one 
comorbidity suggesting that these studies may have underestimated the prevalence of comorbidity, 
in part due to the limited number of comorbidities included for evaluation.  
 
Our study identified comorbidities associated with atopic asthma, such as eczema and chronic 
sinusitis. However in relative terms, the respiratory comorbidities most strongly associated with 
asthma were COPD, closely followed by bronchiectasis. Similar findings in terms of respiratory 
comorbidity were seen in a Canadian study and in a recent meta-analysis of observational 
studies.[20, 21] This association could in part be explained by asthma-COPD overlap syndrome 
(ACOS) that may be caused by long-term uncontrolled airway inflammation leading to airway 
remodelling and fixed airway obstruction, or as a result of COPD developing de novo in people with 
asthma who smoke.[22] These are both potentially modifiable risk factors to preserve respiratory 
function and reduce the risk of respiratory comorbidity in later life. With regards to bronchiectasis, 
people with asthma are at increased risk of lower respiratory tract infections including pneumonia 
that potentially contribute to the development of bronchiectasis.[17] Whilst the diagnosis of asthma 
is often clinical, we did not use objective measures such as lung function or CT scanning to 
differentiate between asthma and COPD or bronchiectasis because these data were not available. 
Due to the cross-sectional nature of our study, we cannot exclude the possibility of coding errors 
contributing to the observed associations and of some misclassification between diagnoses. 
Nevertheless, asthma is a recognised comorbidity in people with bronchiectasis as highlighted by a 
recent prospective international multicentre cohort study and asthma-COPD overlap syndrome is a 
well-recognised entity, with chronic diseases being generally well recorded with these types of 
data.[23] It therefore seems prudent to consider these respiratory comorbidities because they may 
require different treatment approaches or have differential risks of adverse effects from medication, 
such as the risk of pneumonia with inhaled corticosteroids.[24] 
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In contrast, the relationship between asthma and other common comorbidities is more complex. 
The association with reflux disease could result from increased diagnosis from closely related 
symptoms (such as cough) compounded by the use of medicines including oral steroids. Reflux is 
potentially an important comorbidity associated with an increased risk of asthma exacerbations due 
to direct airway contact with gastric acid triggering a vasovagal reflex and bronchospasm.[25] An 
association with hypertension may also be related to the use of chronic inhaled beta2-agonist 
stimulants or in part due to increased blood pressure screening during routine consultations for 
asthma, a feature that may also relate to other comorbidities.[26] The observed association 
between chronic pain and asthma is less understood with only a limited number of studies having 
been performed linking pain and asthma.[27]  
 
Mental health conditions are particular important to consider and our study showed a significant 
association between asthma and several mental health comorbidities, including anxiety and 
depression. Although several international studies have shown depression to be approximately twice 
as common in people with asthma, less consistent associations have been reported with 
anxiety.[19][28][29] Indeed, previous work on multimorbidity has shown that the prevalence of 
mental health conditions rises as the number of comorbid conditions increases, particularly in 
people from more socioeconomically deprived backgrounds, suggesting that a holistic generalist 
approache to asthma care may be required.[14] However, in the UK at least, a perverse ‘invers care 
law’ in primary care funding persists with lower funding relative to multimorbidity burden in 
practices serving more deprived populations.[30][31]  
 
After adjustment for other physical comorbidities, the probability of dementia was significantly 
lower in people with asthma than people without. To our knowledge, only one other study has 
assessed the relationship with dementia, reporting a similar sized association with as ours although 
not statistically significant (adjusted OR 0.64, 95% CI 0.28 to 1.48).[32] This association may partly be 
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related to the definition of asthma used in our study which included diagnostic coding and asthma 
treatment within 12 months of data extraction, and medication adherence could be less likely in 
people with dementia.  
 
International asthma guidelines rely on the highest quality evidence to make recommendations on 
asthma care, much of which results from clinical trials. However, it is well recognised that people in 
clinical trials may not be representative of people with asthma in the general population. Our study 
shows that comorbidity is the norm in people with asthma yet it is rarely reported in important 
clinical trials. For example, the Salmeterol Multicenter Asthma Research Trial which assessed the risk 
of severe exacerbations in people with asthma provides no description of comorbidities among its 
participants.[33] Where comorbidities are reported, it is generally in relation to the exclusion of 
people with significant or serious comorbidities that may be unspecified, for example by excluding 
people with “any other significant medical illnesses”.[34] Such exclusions and underreporting 
potentially affect the generalisability of such evidence which may differ in people with a range of 
comorbidities.[13]  
 
This study has several strengths and limitations. A strength is the large representative population 
used for analysis with data obtained from routinely collected healthcare systems, at a time when GP 
practices were incentivised to keep an up to date register of people with asthma. An important 
limitation is that like other cross-sectional studies, it is only possible to examine associations rather 
than explore causality.[35] This study is reliant on the accuracy of clinical coding and GP electronic 
medical records may not accurately capture all relevant data on asthma such as airway variability. 
However, at the time of data extraction, general practices were financially incentivised to create and 
maintain an accurate register of people with asthma as well as many of the other comorbidities 
examined that was subject to external inspection by the NHS to ensure compliance with contractual 
requirements, with common chronic conditions in UK primary care data being well recorded.[36, 37] 
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The definition included the use of asthma controller medication and was based upon that used by 
the UK Quality and Outcomes Framework, a national pay for performance system which provides 
payment to GPs to keep registers of asthma patients included. This definition excludes those with a 
history of asthma in the past that no longer receive treatment, which are included in the non-asthma 
population. It was also not possible to measure the prevalence of some other comorbidities 
including NSAID-exacerbated respiratory disease which occurs in approximately 9-10% of patients 
with asthma, and for which selective COX-2 inhibitors may be more appropriate in people requiring 
NSAIDs for the treatment of certain comorbidities such as pain and arthritis. [38][39] Finally, further 
analytical work examining the impact of comorbidities on asthma severity, control and health care 
costs is still required for several comorbidities. 
 
In conclusion, this study highlights the significantly greater prevalence of comorbidity in people with 
asthma that clinicians should be aware when reviewing people with asthma. Further studies are 
required to assess the generalizability of evidence in comorbid people with asthma and to evaluate 
generalist approaches to asthma care. 
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Table 1: Characteristics of adults with and without asthma in the dataset 
 
 Adults  
with asthma 
No. (%) 
(N=84505) 
Adults  
without asthma  
No. (%) 
(N=1339873) 
Percentage  
difference 
(95% CI) 
Sex 
 Male 
 Female 
 
34862 (41.3) 
49643 (58.7) 
 
664567 (49.6) 
675306 (50.4) 
 
-8.3 (-8.0 to -8.7) 
8.3 (8.0 to 8.7) 
Smoking Status 
 Non-smoker 
 Ex-smoker 
 Smoker 
 Missing 
 
42206 (49.9) 
20604 (24.4) 
20914 (24.7) 
781 (0.9) 
 
643641 (48.0) 
231448 (17.3) 
328403 (24.5) 
136381 (10.2) 
 
1.9 (1.6 to 2.3) 
7.1 (6.8 to 7.4) 
0.2 (0.1 to 0.5) 
-9.3 (-9.2 to -9.3) 
Age Group (years) 
 18 to 24 
 25 to 44 
 45 to 64 
 65 to 84 
 85 and over 
 
8269 (9.8) 
28573 (33.8) 
28661 (33.9) 
17285 (20.5) 
1717 (2.0) 
 
143424 (10.7) 
479816 (35.8) 
444466 (33.2) 
237315 (17.7) 
34852 (2.6) 
 
-0.9 (-0.7 to -1.1) 
-2.0 (-1.7 to -2.3) 
0.7 (0.4 to 1.1) 
2.7 (2.5 to 3.0) 
-0.6 (-0.5 to -0.7) 
Deprivation (quintiles) 
 Q1 (least deprived) 
 Q2 
 Q3 
 Q4 
 Q5 (most deprived) 
 
14799 (17.5) 
17292 (20.5) 
19473 (23.0) 
17154 (20.3) 
15787 (18.7) 
 
257230 (19.2) 
286862 (21.4) 
302774 (22.6) 
254230 (19.0) 
238777 (17.8) 
 
-1.7 (-1.4 to -2.0) 
-1.0 (-0.6 to -1.2) 
0.5 (  0.2 to  0.7) 
1.3 (1.1 to 1.6) 
0.9 (0.6 to 1.1) 
No. of total 
comorbidities 
 None  
 One  
 Two 
 Three 
 Four or more 
 
 
31577 (37.4) 
18506 (21.9) 
12188 (14.4) 
8449 (10.0) 
13785 (16.3) 
 
 
721362 (53.8) 
269417 (20.1) 
145991 (10.9) 
86943 (6.5) 
116160 (8.7) 
 
 
-16.5 (-16.1 to -16.8) 
1.8 (1.5 to 2.1) 
3.5 (3.3 to 3.8) 
3.5 (3.3 to 3.7) 
7.6 (7.4 to 7.9) 
No. of physical 
comorbidities 
 None 
 One  
 Two 
 Three  
 Four or more 
 
 
37083 (43.9) 
19167 (22.7) 
11585 (13.7) 
7258 (8.6) 
9412 (11.1) 
 
 
800108 (59.7) 
256230 (19.1) 
130557 (9.7) 
72832 (5.4) 
80146 (6.0) 
 
 
-15.8 (-15.5 to -16.2) 
3.6 (3.3 to 3.9) 
4.0 (3.7 to 4.2) 
3.2 (3.0 to 3.4) 
5.2 (4.9 to 5.4) 
No. of mental health 
comorbidities 
 None 
 One 
 Two or more 
 
 
64949 (76.9) 
16119 (19.1) 
3437 (4.1) 
 
 
1138705 (85.0) 
167699 (12.5) 
33469 (2.5) 
 
 
-8.1 (-7.8 to – 8.4) 
6.6 (6.3 to 6.8) 
1.6 (1.4 to 1.7) 
(Total number of comorbidities = Number of physical comorbidities + Number of mental comorbidities)  
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Table 2: Prevalence of comorbid physical conditions in people with and without asthma. 
 
 
 
Physical  
health conditions 
Adults  
with asthma 
No. (%) 
(N=84505) 
Adults  
without asthma 
No. (%) 
(N=1339873) 
 
 
Unadjusted OR 
(95% CI) 
Adjusted for age, 
sex, deprivation, 
smoking 
OR (95% CI) 
COPD 11345 (13.4) 41762 (3.1) 4.82 (4.72 to 4.93) 5.65 (5.52 to 5.79) 
Bronchiectasis 660 (0.8) 2154 (0.2) 4.89 (4.48 to 5.34) 4.65 (4.26 to 5.08) 
Eczema or psoriasis 1766 (2.1) 8603 (0.6) 3.30 (3.14 to 3.48) 3.30 (3.14 to 3.48) 
Dyspepsia (treated) 9251 (10.9) 69953 (5.2) 2.23 (2.18 to 2.28) 2.20 (2.15 to 2.25) 
Chronic sinusitis 1117 (1.3) 8048 (0.6) 2.22 (2.08 to 2.36) 2.12 (1.99 to 2.26) 
Pain 13431 (15.9) 112700 (8.4) 2.06 (2.02 to 2.10) 2.04 (1.99 to 2.08) 
Migraine 1131 (1.3) 8120 (0.6) 2.23 (2.09 to 2.37) 1.97 (1.85 to 2.10) 
Diverticular disease 3121 (3.7) 30692 (2.3) 1.64 (1.58 to 1.70) 1.63 (1.57 to 1.70) 
Viral hepatitis 104 (0.1) 1071 (0.1) 1.54 (1.26 to 1.88) 1.95 (1.59 to 2.38) 
Irritable bowel syndrome 4968 (5.9) 47169 (3.5) 1.71 (1.66 to 1.76) 1.57 (1.53 to 1.62) 
Constipation 3317 (3.9) 33099 (2.5) 1.61 (1.56 to 1.67) 1.57 (1.51 to 1.63) 
Heart Failure 1539 (1.8) 17360 (1.3) 1.41 (1.34 to 1.49) 1.47 (1.39 to 1.55) 
Inflammatory bowel disease 827 (1.0) 8924 (0.7) 1.47 (1.37 to 1.58) 1.42 (1.32 to 1.53) 
Rheumatological disease 4803 (5.7) 53205 (4.0) 1.46 (1.41 to 1.50) 1.41 (1.37 to 1.46) 
Coronary heart disease 6103 (7.2) 75364 (5.6) 1.31 (1.27 to 1.34) 1.39 (1.35 to 1.43) 
Prostate 1045 (1.2) 14188 (1.1) 1.41 (1.33 to 1.51) 1.32 (1.24 to 1.41) 
Thyroid 6076 (7.2) 65867 (4.9) 1.50 (1.46 to 1.54) 1.33 (1.30 to 1.37) 
Diabetes 5727 (6.8) 69104 (5.2) 1.34 (1.30 to 1.38) 1.31 (1.28 to 1.35) 
Epilepsy 953 (1.1) 11431 (0.9) 1.33 (1.24 to 1.42) 1.29 (1.21 to 1.38) 
Hypertension 16986 (20.1) 217328 (16.2) 1.30 (1.28 to 1.32) 1.27 (1.25 to 1.30) 
Deafness 3952 (4.7) 50782 (3.8) 1.25 (1.21 to 1.29) 1.22 (1.18 to 1.27) 
Chronic kidney disease 2427 (2.9) 31139 (2.3) 1.24 (1.19 to 1.30) 1.23 (1.17 to 1.28) 
Atrial fibrillation 1642 (1.9) 222334 (1.7) 1.17 (1.11 to 1.23) 1.21 (1.15 to 1.28) 
Glaucoma 1111 (1.3) 14808 (1.1) 1.19 (1.12 to 1.27) 1.18 (1.11 to 1.26) 
Chronic liver disease 175 (0.2) 2439 (0.2) 1.14 (0.98 to 1.33) 1.27 (1.09 to 1.48) 
Blindness 582 (0.7) 7796 (0.6) 1.19 (1.09 to 1.29) 1.16 (1.06 to 1.26) 
Peripheral vascular disease 1601 (1.9) 21639 (1.6) 1.18 (1.19 to 1.24) 1.20 (1.14 to 1.26) 
Stroke or TIA 2341 (2.8) 34204 (2.6) 1.09 (1.04 to 1.14) 1.10 (1.06 to 1.15) 
Cancer diagnosis within 5 yr. 2863 (3.4) 40801 (3.0) 1.12 (1.07 to 1.16) 1.07 (1.03 to 1.11) 
Parkinson’s Disease 151 (0.2) 2590 (0.2) 0.92 (0.78 to 1.09) 0.94 (0.80 to 1.11) 
Multiple sclerosis 205 (0.2) 3642 (0.3) 0.89 (0.78 to 1.03) 0.83 (0.72 to 0.96) 
Rheumatological disease = Gout, inflammatory arthritis and connective tissue disease. 
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Table 3: Prevalence of comorbid mental health conditions in people with and without asthma 
 
 
Mental  
health conditions 
Adults 
with asthma 
No. (%) 
(N=84505) 
Adults  
without asthma 
No. (%) 
(N=1339873) 
 
 
Unadjusted OR 
(95% CI) 
Adjusted for age, 
sex, smoking, and 
deprivation 
OR (95% CI) 
Adjusted for age, sex, 
deprivation, no. 
physical conditions,  
smoking OR (95% CI) 
Depression 
 
14626 (17.3) 129317 (9.1) 1.96 (1.92 to 2.00) 1.86 (1.82 to 1.90) 1.60 (1.57 to 1.63) 
Anxiety and other neurotic stress 
related and somatoform disorders 
5820 (6.9) 49906 (3.7) 1.91 (1.86 to 1.97) 1.85 (1.80 to 1.90) 1.53 (1.48 to 1.57) 
Alcohol problem 
 
3339 (4.0) 39024 (2.9) 1.37 (1.32 to 1.42) 1.65 (1.59 to 1.71) 1.47 (1.42 to 1.53) 
Anorexia or bulimia 
 
436 (0.5) 4870 (0.4) 1.42 (1.29 to 1.57) 1.31 (1.19 to 1.44) 1.18 (1.07 to 1.30) 
Drug & medication use problem 
 
3450 (4.1) 39010 (2.9) 1.42 (1.37 to 1.47) 1.53 (1.47 to 1.58) 1.25 (1.21 to 1.30) 
Schizophrenia or bipolar disorder 
 
891 (1.1) 11602 (0.9) 1.22 (1.14 to 1.31) 1.26 (1.17 to 1.35) 1.18 (1.10 to 1.27) 
Learning disability 
 
375 (0.4) 4639 (0.3) 1.28 (1.16 to 1.43) 1.24 (1.12 to 1.38) 1.09 (0.98 to 1.21) 
Dementia 
 
446 (0.5) 11250 (0.8) 0.63 (0.57 to 0.69) 0.64 (0.58 to 0.70) 0.60 (0.55 to 0.66) 
 
 
